Rheumatoid Arthritis Diagnostic Tests Market Huge Growth in Coming Years With Profiling Leading Companies| Augurex Life Sciences Corp., Thermo Fisher Scientific Inc., Bio Rad Laboratories Inc

Market Overview:

Rheumatoid arthritis diagnostic tests help identify the presence of rheumatoid arthritis in patients with joint pain and swelling. These tests include serology tests, imaging tests, and others.

Market Dynamics:

The rheumatoid arthritis diagnostic tests market is expected to grow significantly during the forecast period owing to the rising prevalence of rheumatoid arthritis globally. According to the Arthritis Foundation, around 1.3 million US adults have rheumatoid arthritis in 2018, and it is more common in women than in men. Further, rising healthcare expenditure and increasing awareness regarding the early diagnosis of rheumatoid arthritis is also expected to aid market growth over the forecast period. Additionally, ongoing development and introduction of novel diagnostic tests by key players is further expected to boost the market growth. For instance, in October 2021, Thermo Fisher Scientific launched Invida, an autoantibody diagnostic test for rheumatoid arthritis that can provide results within one day.

Get an Exclusive Sample Copy of the Report at: - https://www.coherentmarketinsights.com/insight/request-sample/3716

INCREASED ADOPTION OF AUTOIMMUNE DISEASE TREATMENT

The rheumatoid arthritis diagnostic tests market is witnessing continued growth due to the rising global prevalence of rheumatoid arthritis and increased adoption of autoimmune disease treatment. According to estimates by the World Health Organization, rheumatoid arthritis affects over 0.5-1% of the global population. Early diagnosis and treatment of rheumatoid arthritis is important for slowing disease progression and improving patient outcomes. This has led to a growing demand for various diagnostic tests such as routine blood tests, imaging tests, and disease activity score tests that help accurately diagnose and monitor the condition. Furthermore, the availability of novel targeted therapies and biologic disease-modifying anti-rheumatic drugs has significantly improved treatment efficacy. However, these advanced treatment options come with high costs. Therefore, diagnostic tests play a key role in confirming disease presence, assessing disease severity, treatment response, and guiding therapy management decisions to optimize treatment effectiveness and minimize healthcare expenditures associated with rheumatoid arthritis.

INCREASED RESEARCH INTO DISEASE BIOMARKERS

Ongoing research into potential disease biomarkers for rheumatoid arthritis is another major driver for the market. Currently available diagnostic tests cannot always accurately differentiate rheumatoid arthritis from other arthritis types based on clinical manifestations alone. This has led pharmaceutical companies and research institutes to invest heavily in identifying novel protein, genetic, molecular, and imaging biomarkers that can aid early diagnosis and predict disease progression and treatment response with high sensitivity and specificity. Some of the biomarkers under active investigation include anti-citrullinated protein antibodies, rheumatoid factor, matrix metalloproteinases, cytokines, chemokines, adhesion molecules and genetic variants. The identification and validation of reliable diagnostic biomarkers will facilitate development of simple blood or urine tests with high accuracy for widespread screening and aid therapeutic decision making. This ongoing biomarker research contributes to the development of advanced diagnostic techniques, fueling market growth.

HIGH TREATMENT COST OF BIOLOGICS

While the availability of novel targeted therapies has significantly improved patient outcomes in rheumatoid arthritis, their high costs present a major market barrier. Biologics such as TNF-alpha inhibitors, B-cell depleting therapies, IL-6 inhibitors and JAK inhibitors have transformed rheumatoid arthritis treatment over the past decade. However, their list prices often range from tens of thousands to over a hundred thousand dollars annually per patient. This places a huge financial burden on patients as well as national healthcare systems. Governments and private insurers strive to contain costs by implementing strict treatment guidelines that require confirmation of disease presence and severity through diagnostic tests prior to approving expensive biologic therapies. While this containment of costs helps sustain the healthcare system, it also presents reimbursal challenges for diagnostic test makers. Moreover, budget limitations could restrict patient access to novel but costly diagnostic techniques, slowing their market uptake. High biologic treatment expenses hence pose both a challenge as well as opportunity for the rheumatoid arthritis diagnostic tests market.

INCREASING ADOPTION OF PRECISION MEDICINE APPROACH

The rising adoption of precision or personalized medicine approach in rheumatoid arthritis treatment presents a major market opportunity. Traditionally, treatment initiation and monitoring in rheumatoid arthritis has followed a trial-and-error process without consideration for inter-individual differences in drug metabolism, underlying disease characteristics or biomarkers. This has resulted in treatment failures and delays in response for some patients. However, precision medicine aims to integrate individual patient characteristics, including biomarkers, genetics, phenotypic features and lifestyle factors to make clinical decisions. This allows selection of the most appropriate treatment approach or sequence for each individual based on their disease signature. It is expected to enable more targeted intervention and optimization of long term outcomes. The higher demand for informative diagnostic tests to support precision treatment protocols will provide significant momentum to the rheumatoid arthritis diagnostic tests market. Leading pharmaceutical companies are actively collaborating with diagnostic makers to co-develop companion diagnostics to guide personalized usage of novel arthritis drugs.

INCREASING ADOPTION OF PRECISION MEDICINE APPROACH

A key trend positively impacting the rheumatoid arthritis diagnostic tests market is the increasing shift from invasive procedures to non-invasive and minimally invasive techniques. Conventional diagnostic procedures such as joint aspiration and biopsy are being replaced by advanced imaging modalities and biomarker-based tests.

List of TOP Players in Market Report are: -

◘ Abbott Diagnostics (Abbott Laboratories)
◘ Labcorp ,Antibodies Inc.
◘ Networks LLC
◘ Beckman Coulter Inc.
◘ Euro Diagnostica AB
◘ F. Hoffmann-La Roche Ltd.
◘ Qiagen NV
◘ Siemens Healthcare GmbH
◘ Augurex Life Sciences Corp.
◘ Thermo Fisher Scientific Inc.
◘ Bio Rad Laboratories Inc.
◘ Exagen Inc.
◘ Genway Biotech Inc.
◘ Microdrop LLC (imaware)
◘ Svar Life Science AB
◘ and Thermo Fisher Scientific Inc.

Note: Major Players are sorted in no particular order.

Market Detailed Segmentation:

By Test Type:

Serology Test
Erythrocyte Sedimentation Rate (ESR)
Rheumatoid Factor (RF)
Anti-cyclic Citrullinated Peptide (anti-CCP)
Antinuclear Antibody (ANA)
Uric Acid
Other Tests
Monitoring RA Treatment Efficiency Tests
Salicylate Level Count
Muscle Enzyme Tests (CPK, Aldolase)
Creatinine Test

By End User:

Diagnostic Laboratories
Private Laboratories
Public Laboratories
Ambulatory Surgical Centers

Buy This Premium Report and Get Upto 25 % OFF: https://www.coherentmarketinsights.com/insight/buy-now/3716

Furthermore, the years considered for the study are as follows:

Historical data - 2016-2021
The base year for estimation - is 2021
Estimated Year - 2023
Forecast period** - 2023 to 2030

This Rheumatoid Arthritis Diagnostic Tests Market Research/Analysis Report Contains Answers to your following Questions:

◈What are the current global trends in the Rheumatoid Arthritis Diagnostic Tests market, and will the market experience an increase or decrease in demand in the upcoming years?

◈ What is the expected demand for various product types within the Rheumatoid Arthritis Diagnostic Tests market, and what are the emerging Market applications and trends?

◈ What are the projections for the global Rheumatoid Arthritis Diagnostic Tests Market in terms of capacity, production, production value, cost, profit, market share, supply, consumption, import, and export?

◈ How will strategic developments shape the Market trajectory in the medium to long term?

◈ What factors contribute to the final price of Rheumatoid Arthritis Diagnostic Tests , and what are the raw materials used in its manufacturing?

◈ What is the market's growth potential, particularly with the increasing adoption of Rheumatoid Arthritis Diagnostic Tests in mining?

◈ What is the current and 2022 value of the global market, and who are the leading companies in this market?

◈ What recent Market trends can be leveraged to create additional revenue streams?

◈ What entry strategies, economic impact mitigation measures, and marketing channels should be considered for the Rheumatoid Arthritis Diagnostic Tests Market?

Summarized Extracts from TOC of Market Study

Chapter 1 Rheumatoid Arthritis Diagnostic Tests Introduction and Market Overview

1.1 Objectives of the Study

1.2 Overview of Rheumatoid Arthritis Diagnostic Tests

1.3 Scope of The Study

1.3.1 Key Market Segments

1.3.2 Players Covered

1.3.3 COVID-19's impact on the Rheumatoid Arthritis Diagnostic Tests industry

1.4 Methodology of The Study

1.5 Research Data Source

Chapter 2 Executive Summary

Chapter 3 Industry Chain Analysis

Chapter 4 Market, by Type

Chapter 5 Market, by Application

Chapter 6 Market Analysis by Regions

Chapter 7 North America Market Analysis by Countries

Chapter 8 Europe Rheumatoid Arthritis Diagnostic Tests Market Analysis by Countries

Chapter 9 Asia Pacific Rheumatoid Arthritis Diagnostic Tests Market Analysis by Countries

Chapter 10 Middle East and Africa Rheumatoid Arthritis Diagnostic Tests Market Analysis by Countries

Chapter 11 South America Rheumatoid Arthritis Diagnostic Tests Market Analysis by Countries

Chapter 12 Competitive Landscape

Chapter 13 Industry Outlook

Chapter 14 Market Forecast

Chapter 15 New Project Feasibility Analysis

Contact Us

Mr. Shah
Coherent Market Insights Pvt Ltd,
533 Airport Boulevard, Suite 400, Burlingame,
CA 94010, United States
Phone: US +12067016702 / UK +4402081334027
JAPAN:+81-50-5539-1737
INDIA:+91-848-285-0837
Email: sales@coherentmarketinsights.com

About Coherent Market Insights

Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

This release was published on openPR.